logo
Hantavirus, cause of Gene Hackman's wife's death, kills three in California

Hantavirus, cause of Gene Hackman's wife's death, kills three in California

Fox News07-04-2025

Hantavirus, the disease that caused the death of Betsy Arakawa, actor Gene Hackman's wife, has claimed the lives of three people in California.
After Arakawa, 65, was found dead along with Hackman, 95, on Feb. 26, authorities confirmed her cause of death as "hantavirus pulmonary syndrome" (HPS), while Hackman succumbed to atherosclerotic cardiovascular disease along with advanced Alzheimer's disease.
Now, Mono County Public Health has confirmed a total of three deaths due to hantavirus in Mammoth Lakes, a town in California's Sierra Nevada mountains.
Hantaviruses include a group of viruses primarily carried by rodents that can cause severe respiratory or renal diseases in humans, according to Dr. Rhys Parry, a molecular virologist at the University of Queensland in Australia.
Most hantaviruses that are found in North, Central and South America can cause HPS. The disease has a nearly 40% fatality rate in those who are infected.
All three of the recent California cases have been fatal, which Dr. Tom Boo, Mono County's public health officer described as "tragic and alarming."
"We don't have a clear sense of where this young adult may have contracted the virus," Boo said in a press release.
"An increase in indoor mice elevates the risk of hantavirus exposure."
One person had "numerous mice" in their home, but no evidence of mice was found in the other two homes, the release stated.
"The occurrence of three cases in a short period has me worried, especially this early in the year," Boo said.
"We observed some mice in the workplace, which is not unusual for indoor spaces this time of year in Mammoth Lakes," he went on. "We haven't identified any other activities in the weeks before illness that would have increased this person's exposure to mice or their droppings."
Hantavirus cases are usually seen in the area in late spring and summer, the public health officer stated.
Seeing three cases this early in the year is "strikingly unusual."
"We believe that deer mouse numbers are high this year in Mammoth (and probably elsewhere in the Eastern Sierra)," Boo wrote. "An increase in indoor mice elevates the risk of Hantavirus exposure. Therefore, it is crucial to take precautions."
None of the infected individuals engaged in activities that would have exposed them to the virus, such as cleaning out poorly ventilated indoor areas or outbuildings with a lot of mouse waste, the official went on.
"Instead, these folks may have been exposed during normal daily activities, either in the home or the workplace," he said.
"Many of us encounter deer mice in our daily lives and there is some risk. We should pay attention to the presence of mice and be careful around their waste."
"Hantaviruses typically spread when humans breathe in virus particles from disturbed rodent urine, droppings or nesting materials," Parry previously told Fox News Digital.
The hantaviruses found in the U.S. are not known to spread between people, according to the CDC.
Other mechanisms of spread, according to the CDC, include breathing in contaminated air when cleaning up after rodents, touching contaminated objects and then touching the nose or mouth, getting bitten or scratched by an infected rodent, and eating food contaminated with the virus.
Dr. Marc Siegel, clinical professor of medicine at NYU Langone Health and Fox News senior medical analyst, agreed that hantavirus can spread via dust from rodents' saliva, urine and places they touch.
IMAGE
The most common type of rodent to carry it in the U.S. is the deer mouse, the doctor confirmed.
Most hantavirus cases are seen in rural areas, where it is more likely for rodents to get into homes or barns, the CDC noted.
Siegel added that it rarely affects humans "because only some of the rodents have it, and they don't all come into contact — but one-third to one-half of cases are fatal."
Early symptoms of hantavirus include fever, muscle aches, fatigue and gastrointestinal issues that appear anywhere from one to eight weeks after exposure, according to Parry.
"These progress to serious respiratory symptoms like coughing, shortness of breath and fluid in the lungs four to 10 days later," he said.
Sin Nombre virus is the most common hantavirus in the United States, which causes hantavirus pulmonary syndrome with a mortality rate of approximately 38%.
"It typically becomes fatal when the lungs fill with fluid, leading to respiratory failure and insufficient oxygen reaching vital organs," Parry noted.
There is no specific antiviral treatment for hantavirus, the expert said, although early intensive care with oxygen therapy and supportive measures is crucial.
"Early intensive medical care is critical because patients who have sudden acute disease can rapidly become severely sick and die," the CDC states.
"If a patient is experiencing full distress, it is less likely the treatment will be effective."
Supportive care can include monitoring heart function, administering fluids and oxygen, and placing the patient on a ventilator as needed. Patients may also receive broad-spectrum antibiotic therapy, fever reducers and pain relievers.
"Early intensive medical care is critical, because patients who have sudden acute disease can rapidly become severely sick and die."
"Although there is no cure for hantavirus pulmonary syndrome, it is important to seek medical care when short of breath, because the patient may need support from a mechanical ventilator or extra-corporal membrane oxygenator (ECMO) machine to deliver enough oxygen to their body," Dr. Sonja Bartolome, an expert in pulmonology and critical care at UT Southwestern Medical Center, previously told Fox News Digital.
"Even with medical care, 30% to 40% of people who develop hantavirus pulmonary syndrome will not survive."
To prevent the virus from spreading, Mono County Public Health recommended sealing up gaps in the home to prevent mice from entering and storing food in rodent-proof containers.
They also advised against vacuuming or sweeping rodent droppings, nests or urine, as that can stir up the virus into the air.
Any contaminated areas should be sprayed with a disinfectant or a freshly made 10% bleach solution, they recommended, and any enclosed areas should be aired out for at least 30 minutes before activities.
For more Health articles, visit www.foxnews.com/health
People should wear gloves and an N-95 mask when cleaning contaminated areas.
"Do not eat food that may have been contaminated by rodents, and always wash your hands thoroughly after any potential exposure," health officials added.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Psychedelics as potential mental health treatment are explored by Trump administration
Psychedelics as potential mental health treatment are explored by Trump administration

Yahoo

timean hour ago

  • Yahoo

Psychedelics as potential mental health treatment are explored by Trump administration

The Trump administration has expressed interest in exploring psychedelics for their potential in treating PTSD and other debilitating mental health issues, various officials have shared. "The Department shares the goal of ensuring that all Americans — especially our nation's veterans — have access to safe and effective treatments for conditions such as PTSD, addiction and depression," a spokesperson for the U.S. Department of Health and Human Services (HHS), run by Sec. Robert J. Kennedy Jr., said in a statement provided to Fox News Digital. "Secretary Kennedy is committed to applying rigorous, evidence-based science to research efforts aimed at addressing these serious health challenges." Fda Approves First Ai Tool To Predict Breast Cancer Risk In recent years, researchers have been actively investigating the potential of psychedelics, such as MDMA and psilocybin ("magic mushrooms") to treat mental health disorders. MDMA is not approved for clinical use by the U.S. Food and Drug Administration (FDA), but can be studied in clinical settings. Read On The Fox News App Psilocybin is listed as a Schedule I substance under the Controlled Substances Act, which means it has "a high potential for abuse, [is not] currently accepted for medical use in treatment in the United States, and [has] a lack of accepted safety for use under medical supervision." Psilocybin-assisted therapy, however, is legal in Oregon, Colorado and New Mexico. Psychedelic medicines are "showing real promise," according to Dr. Luke Twelves, general practitioner and vice president of medical for Lindus Health in London. Clinical trials have found such treatments safe and effective for patients battling serious mental health issues, according to Twelves. Common Supplements And Medications Could Cause Liver Damage, Studies Show "Take psilocybin, for example — it's demonstrating remarkable results for severe depression that hasn't responded to other medications," he told Fox News Digital. "MDMA is showing similar breakthroughs for PTSD treatment." Clinical trials are also investigating how psychedelics could help with end-of-life anxiety, addiction, eating disorders, chronic pain and OCD, he added. Researchers have faced challenges in terms of regulatory hurdles and proper placebo controls, Twelves said. "Given that these treatments could transform [the] lives of people suffering from conditions where nothing else has worked effectively, it's crucial that we complete this research properly," he said. "The goal is to bring safe, proven psychedelic therapies to the patients who need them most." At President Trump's May 1 cabinet meeting, Department of Veterans Affairs Secretary Doug Collins said that "we're opening up the possibility of psychedelic treatment." Retired Army Sergeant Jonathan Lubecki recently told Fox News' Alexandria Hoff that MDMA stopped his PTSD while he was participating in a clinical trial. "[I] took my first dose of MDMA. I've only taken it three times as part of the clinical trial, haven't taken it since, and haven't found the need to take it since, because I haven't had PTSD," he said. Peter Kasperowicz, Department of Veterans Affairs press secretary, told Fox News Digital the department is safely exploring all avenues that promote the health of veterans. Fallujah Vet Turns Medal Of Heroism Into A Healing Mission For Fellow Warriors With Service Dogs Program "Preliminary findings have produced positive results on psychedelic-assisted therapies for treating mental health conditions," he said. The VA is currently running 11 clinical trials in various phases, with a total of some 800 veterans expected to participate. "The goal of these trials is to determine whether compounds such as MDMA and psilocybin can treat veterans with post-traumatic stress disorder, treatment-resistant depressive disorder, major depressive disorder and potentially other mental health conditions," said Kasperowicz. An MDMA study published in the Jan. 2025 issue of The American Journal of Psychiatry found that the substance is "unlike classical psychedelics." The study noted, "MDMA allows the individual to maintain intact ego functioning and a greater degree of cognitive and perceptual lucidity while still experiencing a prosocial altered state of consciousness that facilitates deeply emotional therapeutic breakthroughs." Click Here To Sign Up For Our Health Newsletter The researchers concluded that MDMA showed "enhanced levels of trust, empathy, self-compassion and a 'window of tolerance'" that traditional psychotherapy lacks. Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin, told Fox News Digital that "the time is now to address the mental health crisis." He said it is "gratifying" that administration officials value the potential benefits of looking into alternative mental health treatments. Cybin is currently in phase 3 of a study of CYB003, a type of psilocybin that has been granted breakthrough therapy designation by the FDA as an additional treatment for major depressive disorder (MDD). "In Cybin's completed Phase 2 MDD study, long-term efficacy results showed that 71% of participants were in remission from depression, and 100% of participants responded to treatment at 12 months after just two 16 mg doses of CYB003," said Drysdale. Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and Fox News' senior medical analyst, previously interviewed two of the country's top researchers on psychedelics — Dr. Rachel Yehuda, founder and director of the Center for Psychedelic Psychotherapy and Trauma Research at Mt. Sinai in New York, and Dr. Charles Marmar, director of the PTSD research program at NYU Langone. "They agree there is therapeutic potential if very carefully studied under very strict medical guidance, but there is a huge downside in terms of unregulated recreational uses," Siegel told Fox News Digital at the time. "Both doctors see likely therapeutic value to psychedelics if carefully managed by medical experts," Siegel added. Ryan Moss, chief science officer at Filament Health, a clinical-stage natural psychedelic drug development company in Canada, emphasized it's important to administer psychedelics in a safe setting when treating mental health conditions. For more Health articles, visit "Psychedelic experiences can sometimes feature anxiety, hallucinations and paranoia," Moss previously told Fox News Digital. "Some patients using traditional psychedelics have reported experiencing adverse cardiovascular events during clinical trials." To mitigate these risks, Moss recommended clinical trial participants receive thorough preparation and monitoring by trained professionals during sessions. Melissa Rudy and Angelica Stabile, both of Fox News Digital, contributed article source: Psychedelics as potential mental health treatment are explored by Trump administration

IVF parents are spending thousands to predict their babies' chances of having Alzheimer's, cancer and heart disease
IVF parents are spending thousands to predict their babies' chances of having Alzheimer's, cancer and heart disease

Yahoo

time12 hours ago

  • Yahoo

IVF parents are spending thousands to predict their babies' chances of having Alzheimer's, cancer and heart disease

Maybe she's born with it, maybe it's … genetic optimization? Prospective parents using in vitro fertilization (IVF) will soon be able to select embryos based on their potential risk for diseases — including illnesses that develop later in life — thanks to a groundbreaking $5,999 service announced this week by a US biotech company. 'Before there's a heartbeat, there's DNA,' Kian Sadeghi, founder and chief executive of Nucleus Genomics, said in a statement. 'One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage.' The popular fertility treatment involves removing eggs from a woman's ovaries and fertilizing them with sperm in a lab. The resulting embryo — which could be frozen or fresh — is placed into the uterus, where it hopefully implants in the uterine wall and sparks a pregnancy. Before implantation, many IVF clinics already screen embryos for genetic abnormalities — such as extra chromosomes or gene mutations — that can lead to failed implantations, miscarriages, birth defects or inherited disorders. But the first-of-its-kind service from Nucleus Genomics takes things a step further. The company just launched Nucleus Embryo, a new software platform that lets potential parents dig deep into the full genetic blueprint of their embryos before choosing which one to implant. The tool lets IVF patients compare the DNA of up to 20 embryos, screening them for more than 900 conditions — including Alzheimer's, Type 2 diabetes, heart disease and several forms of cancer. It doesn't stop there. The program also flags potential mental health conditions like depression and schizophrenia and even ranks cognitive traits like IQ. Parents can also get a look at cosmetic and physical features, from height, baldness and BMI to eye and hair color. The company isn't promising perfection. Instead, the software generates a so-called polygenic risk score that will give parents the probability of how likely it is an embryo might develop certain traits or diseases. Ultimately, it's up to the parents to decide which qualities matter most to them. For those looking to decode the results, genetic counseling sessions are available. 'Lifespan has dramatically increased in the last 150 years,' Sadeghi told the Wall Street Journal. 'DNA testing to predict and reduce chronic disease can make it happen again.' The practice, known as polygenic embryo screening, is already highly controversial in the medical world, according to a report published by Harvard Law School's Petrie-Flom Center. Critics warn that allowing parents to screen embryos for risks like depression or diabetes could deepen stigma and discrimination against people living with those conditions. Meanwhile, disability advocates argue it promotes the harmful idea that disability is something to be fixed, not a natural part of human diversity. And when it comes to choosing embryos for traits like intelligence or athleticism, critics say we're sliding into designer baby territory — a modern form of eugenics that favors the rich, reinforcing social and healthcare inequalities. Still, the public appears open to some aspects of the tech. A 2023 survey found that 77% of Americans support using it to screen embryos for the likelihood of developing certain physical conditions, while 72% back screening for mental health risks. Proponents argue it's no different from vaccination — a preventive tool, not a judgment on those with the condition. But when it comes to non-medical traits, support drops fast: only 36% back screening embryos for behavioral traits and just 30% for physical features like height or eye color.

Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory
Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory

Yahoo

time21 hours ago

  • Yahoo

Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory

We came across a bullish thesis on Alpha Cognition Inc. Common Stock (ACOG) by anygal on r/investing on Reddit. In this article, we will summarize the bulls' thesis on ACOG. Alpha Cognition Inc. Common Stock (ACOG)'s share was trading at $9.33 as of 30th May. ACOG's forward P/E was 26.88 according to Yahoo Finance. A chemist in a laboratory analyzing data from the various therapeutic tests conducted. Alpha Cognition Inc. (NASDAQ: ACOG) represents a potentially overlooked opportunity in the Alzheimer's treatment space, having recently launched its oral drug, Zunveyl, at the end of March. With a current market cap of $150 million and $45 million in cash, the company is targeting the underserved segment of the Alzheimer's population—specifically, the 50% of patients in long-term care (LTC) not taking any current medications due to severe side effects. Unlike other galantamine-based drugs, Zunveyl significantly slows disease progression and improves short-term memory with a markedly better safety profile—only one serious side-effect case was reported in its Phase 3 trials, versus a 50% rate seen in traditional options. The drug's Medicare coverage further eases affordability, lowering monthly out-of-pocket costs to $30–$190. Initial demand appears promising, with nearly 500 patients starting treatment in the first two weeks of launch. Even a modest 1% market penetration into the LTC segment could yield $135 million in annual revenue, with $67.5 million in net income assuming 50% margins. A 5% penetration would put net income at $675 million, dwarfing the current valuation. Alpha Cognition has also secured a distribution deal with a major Chinese pharmaceutical firm, creating a royalty-based revenue stream in Asia. While the upside is substantial, key risks remain—most notably, the emergence of unforeseen serious side effects post-launch, which could lead to FDA scrutiny or suspension of sales. Still, the market's underreaction and the company's positioning as a safer, effective alternative in a high-need space make ACOG a high-upside, high-conviction bet for risk-tolerant investors. Previously, we have covered ACOG in March 2025 wherein we summarized a by BullishDoctor on Twitter. The user highlighted that Alpha Cognition Inc.'s drug ZUNVEYL addressed the major side effects of existing Alzheimer's treatments, making it highly tolerable and poised for adoption in long-term care facilities, a $2 billion market. The company was pre-revenue but launched in March 2025 with strong physician support, a nearly complete sales force, and promising catalysts like a Phase 4 study and sublingual formulation, projecting breakeven within three years. Since our last coverage, the stock is up 61% as of 30th May. Alpha Cognition Inc. Common Stock (ACOG) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 8 hedge fund portfolios held ACOG at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of ACOG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store